These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 27296321

  • 1. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, Caiello I, Davì S, Schulert G, Ravelli A, Grom AA, de Min C, De Benedetti F.
    Ann Rheum Dis; 2017 Jan; 76(1):166-172. PubMed ID: 27296321
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sudden Hypotension and Increased Serum Interferon-γ and Interleukin-10 Predict Early Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis.
    Guo L, Xu Y, Qian X, Zou L, Zheng R, Teng L, Zheng Q, Leung Jung LK, Lu M.
    J Pediatr; 2021 Aug; 235():203-211.e3. PubMed ID: 33581106
    [Abstract] [Full Text] [Related]

  • 4. An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
    Arduini A, Marasco E, Marucci G, Pardeo M, Insalaco A, Caiello I, Moneta GM, Prencipe G, De Benedetti F, Bracaglia C.
    Pediatr Rheumatol Online J; 2019 May 22; 17(1):25. PubMed ID: 31118063
    [Abstract] [Full Text] [Related]

  • 5. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Lee PY, Schulert GS, Canna SW, Huang Y, Sundel J, Li Y, Hoyt KJ, Blaustein RB, Wactor A, Do T, Halyabar O, Chang MH, Dedeoglu F, Case SM, Meidan E, Lo MS, Sundel RP, Richardson ET, Newburger JW, Hershfield MS, Son MB, Henderson LA, Nigrovic PA.
    Ann Rheum Dis; 2020 Feb 22; 79(2):225-231. PubMed ID: 31707357
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Single center clinical analysis of macrophage activation syndrome complicating juvenile rheumatic diseases.
    Huang S, Liu Y, Yan W, Zhang T, Wang P, Zhu M, Zhang X, Zhou P, Fan Z, Yu H.
    Pediatr Rheumatol Online J; 2024 May 23; 22(1):58. PubMed ID: 38783316
    [Abstract] [Full Text] [Related]

  • 9. Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis.
    Brossard P, Laveille C.
    Rheumatol Ther; 2024 Jun 23; 11(3):869-880. PubMed ID: 38662147
    [Abstract] [Full Text] [Related]

  • 10. Performance of interferon-gamma levels may lead to earlier diagnosing macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Lu M, Teng L, Xu Y, Xu X.
    Pediatr Rheumatol Online J; 2023 Oct 12; 21(1):115. PubMed ID: 37828529
    [Abstract] [Full Text] [Related]

  • 11. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
    Yasin S, Fall N, Brown RA, Henderlight M, Canna SW, Girard-Guyonvarc'h C, Gabay C, Grom AA, Schulert GS.
    Rheumatology (Oxford); 2020 Feb 01; 59(2):361-366. PubMed ID: 31326996
    [Abstract] [Full Text] [Related]

  • 12. Monocytes From Patients With Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Are Hyperresponsive to Interferon Gamma.
    Pascarella A, Bracaglia C, Caiello I, Arduini A, Moneta GM, Rossi MN, Matteo V, Pardeo M, De Benedetti F, Prencipe G.
    Front Immunol; 2021 Feb 01; 12():663329. PubMed ID: 33815425
    [Abstract] [Full Text] [Related]

  • 13. A dysregulated interleukin-18-interferon-γ-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis.
    Hinze T, Kessel C, Hinze CH, Seibert J, Gram H, Foell D.
    Rheumatology (Oxford); 2021 Nov 03; 60(11):5165-5174. PubMed ID: 33576397
    [Abstract] [Full Text] [Related]

  • 14. Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome.
    Schulert GS, Pickering AV, Do T, Dhakal S, Fall N, Schnell D, Medvedovic M, Salomonis N, Thornton S, Grom AA.
    Ann Rheum Dis; 2021 May 03; 80(5):617-625. PubMed ID: 33277241
    [Abstract] [Full Text] [Related]

  • 15. Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Gorelik M, Fall N, Altaye M, Barnes MG, Thompson SD, Grom AA, Hirsch R.
    J Rheumatol; 2013 Jul 03; 40(7):1191-9. PubMed ID: 23678162
    [Abstract] [Full Text] [Related]

  • 16. Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.
    Shimizu M, Inoue N, Mizuta M, Nakagishi Y, Yachie A.
    Clin Exp Immunol; 2018 Mar 03; 191(3):349-355. PubMed ID: 28815559
    [Abstract] [Full Text] [Related]

  • 17. Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome.
    Prencipe G, Caiello I, Pascarella A, Grom AA, Bracaglia C, Chatel L, Ferlin WG, Marasco E, Strippoli R, de Min C, De Benedetti F.
    J Allergy Clin Immunol; 2018 Apr 03; 141(4):1439-1449. PubMed ID: 28807602
    [Abstract] [Full Text] [Related]

  • 18. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
    Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, Husami A, Watts A, Brunner HI, Huggins J, Mellins ED, Morgan EM, Ting T, Trapnell BC, Wikenheiser-Brokamp KA, Towe C, Grom AA.
    Arthritis Rheumatol; 2019 Nov 03; 71(11):1943-1954. PubMed ID: 31379071
    [Abstract] [Full Text] [Related]

  • 19. Systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome due to a CASP1 variant causing inflammasome hyperactivation.
    Jørgensen SE, Christiansen M, Høst C, Glerup M, Mahler B, Lausten MM, Gad HH, Hartmann R, Herlin T, Mogensen TH.
    Rheumatology (Oxford); 2020 Oct 01; 59(10):3099-3105. PubMed ID: 32556329
    [Abstract] [Full Text] [Related]

  • 20. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
    Put K, Brisse E, Avau A, Imbrechts M, Mitera T, Janssens R, Proost P, Fallarino F, Wouters CH, Matthys P.
    PLoS One; 2016 Oct 01; 11(2):e0150075. PubMed ID: 26914138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.